Grace Halsey

Moderna announced safety and efficacy data from the phase 3 COVE trial that found mRNA-1273 94.5% effective in preventing infection with SARS-CoV-2.

AHA 2020: Daily supplementation with 2000 IU of vitamin D3/day and/or 840 mg omega-3 fatty acids/day did not reduce or increase risk of incident atrial fibrillation.

AHA: DAPD-CKD investigator Prof John McMurray talks to Patient Care about the “revolutionary” findings he will highlight at the AHA sessions on opening day.

Finerenone, a non-steroidal, selective MRA, has distinct advantages over current treatments for diabetic kidney disease. Dr Bakris details these and the FIDELIO results.

AHA 2020 Virtual Scientific Sessions: Nearly one-third of racial disparities in hypertension treatment may be linked to inequities in treatment intensification, study authors suggest.

AHA 2020 Virtual Scientific Sessions: Cumulative exposure, exposure intensity, and number of household smokers in childhood all impact adult heart function, study authors found.

AHA 2020 Virtual Scientific Sessions: Healthy lifestyle habits are inversely associated with-all cause mortality, study authors found.

The novel monoclonal antibody could bring relief to millions of persons with severe, uncontrolled asthma, including those with a low eosinophil phenotype.

Preview days 4 and 5 of the American Heart Association 2020 live late-breaking science sessions. Decide what you need to watch and when.

What to watch during the AHA 2020 late-breaking science sessions? We break down the first 3 days of clinical trial presentations for you, here.

Pfizer/BioNTech announced more than 90% efficacy for their vaccine against SARS-CoV-2 infection in the first interim analysis of phase 3 study.

FDA approval is based on results of the phase III THALES trial, in which DAPT with ticagrelor and aspirin for 30 days reduced the rate of stroke and death by 17% vs aspirin alone.

Use of the myCOPD app after hospitalization for acute COPD exacerbation reduced subsequent exacerbations by nearly 50%, according to study authors.

Obesity, a complex chronic disease in itself, underlies many of the fatal cardiac and cardiometabolic diseases of the 21st century. Find a wide collection of expert guidance in this collection.

Video: Obesity expert Dr Louis Aronne outlines the role of medication in obesity treatment and says primary care is absolutely the place to begin.

Obese patients hospitalized with COVID-19 had lower levels of inflammation biomarkers but outcomes similar to non-obese patients with elevated levels of those biomarkers.

A longitudinal study of weight reduction in adolescents was redesigned to accommodate pandemic lockdown--and the results are very concerning.

Dr Jonathan Chow reviews study findings that patients with COVID-19 taking low-dose aspirin had reduced risk for use of ICU, mechanical ventilation, and of death.

Recent NIH COVID-19 guideline updates include evidence-based considerations for treatment of patients hospitalized with flu and COVID-19 coinfection.

Carl "Chip" Lavie, MD, author of the original book titled, "The Obesity Paradox" explains the paradox of metabolic health in the obese, how it wanes, and an essential element to maintain it.

Reduced risk of mortality as well as of ICU admission and mechanical ventilation were observed in patients with COVID-19 taking daily aspirin for CV prevention.

The investigational mineralocorticoid receptor antagonist slowed progression to renal failure by 18% and reduced the composite cardiovascular outcome by 14%, authors report.

The first study to compare COVID-19 and influenza complications in hospitalized patients found COVID-19 patients more likely to be admitted to ICU and to die.

The new guideline section stresses that testing is the only way to accurately discriminate between the 2 viruses and advises on influenza vaccination and treatment.

Elevated lipoprotein A is a genetically determined independent risk factor for CVD, affecting up to 30% of the population. Phase 3 trials for the first treatment are underway.

Most HF patients were aking more than 5 medications on admission. The majority left taking more than 10, most not indicated for cardiovascular-related conditions.

The FDA has issued guidance for sponsors of requests for EUA for COVID-19 vaccines including details on clinical trial data required to support award of EUA.

From daily aspirin to RGN-CoV2 to zinc, the president of the United States has been treated for COVID-19 with a wide range of both authorized and unproven therapies.

In COPD patients, a new study found no association between lung function decline and individual CVD outcomes, but disease exacerbations and dyspnea were implicated.

The FDA called for more detailed information on risks associated with benzodiazepine use based on review of adverse event reports dating from 1968.